浙江大洋生物科技集团股份有限公司 独立董事 2024 年度述职报告（姜晏） 作为浙江大洋生物科技集团股份有限公司（以下简称"公司"）的独立董事， 2024 年度，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 等法律法规和《公司章程》《公司独立董事工作制度》的规定，在 2024 年度工作 中恪尽职守、勤勉尽责地履行职责，认真审议董事会各项议案，并对相关事项发 表独立意见，充分发挥了独立董事的独立性和专业性的作用，切实维护公司整体 利益和全体股东尤其是中小股东的合法权益。现就 2024 年度的履职情况汇报如 下： 一、独立董事基本情况 本人姜晏，汉族，1975 年出生，中国国籍，无境外永久居留权，大专学历。 2016 年 3 月至 2020 年 8 月，杭州泛优会计师事务所（普通合伙），担任合伙人。 2020 年 8 月至今任职中兴财光华会计师事务所（特殊普通合伙），主要从事并 购和投资财务尽职调查工作，香港上市财务顾问和财税咨询工作。现任大洋生物 独立董事，兼任上海豪末投资管理有限公司执行董事兼总经理、江苏诺泰澳赛诺 生物制药有限公司董事、华纬科技股份有限公司独立董事、浙江众鑫环保科技集 团股份 ...

浙江大洋生物科技集团股份有限公司 独立董事 2024 年度述职报告（韩秋燕） 作为浙江大洋生物科技集团股份有限公司（以下简称"公司"）的独立董事， 2024 年度，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 等法律法规和《公司章程》《公司独立董事工作制度》的规定，在 2024 年度工作 中恪尽职守、勤勉尽责地履行职责，认真审议董事会各项议案，并对相关事项发 表独立意见，充分发挥了独立董事的独立性和专业性的作用，切实维护公司整体 利益和全体股东尤其是中小股东的合法权益。现就 2024 年度的履职情况汇报如 下： 一、独立董事基本情况 本人韩秋燕，1963 年 8 月出生，中国国籍，无境外永久居留权，中共党员， 大学学历。现为国家石油和化学工业规划院（原化学工业部规划院）教授级高工， 副总工程师。1985 年毕业于华东理工大学精细化工系，并获得精细化工学士学 位，教授级高级工程师，国家注册咨询工程师（化工医药）。自参加工作以来， 先后参加了"八五"和"九五""十一五"和"十二五"精细化工规划，执笔完 成了精细化工及化工新材料产业的第十个五年发展规划，参加了《石油和化工工 业"十三五"规划》中期评 ...

对独立董事独立性评估的专项意见 浙江大洋生物科技集团股份有限公司董事会 2025 年 4 月 18 日 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等要求， 浙江大洋生物科技集团股份有限公司（以下简称"公司"）董事会，就公司在任 独立董事韩秋燕女士、曾爱民先生、姜晏先生的独立性情况进行评估并出具如下 专项意见： 浙江大洋生物科技集团股份有限公司董事会 经核查独立董事韩秋燕女士、曾爱民先生、姜晏先生的任职经历以及签署的 相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可 能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规 范运作》中对独立董事独立性的相关要求。 ...

浙江大洋生物科技集团股份有限公司 独立董事 2024 年度述职报告（曾爱民） 作为浙江大洋生物科技集团股份有限公司（以下简称"公司"）的独立董事， 2024 年度，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 等法律法规和《公司章程》《公司独立董事工作制度》的规定，在 2024 年度工 作中恪尽职守、勤勉尽责地履行职责，认真审议董事会各项议案，并对相关事项 发表独立意见，充分发挥了独立董事的独立性和专业性的作用，切实维护公司整 体利益和全体股东尤其是中小股东的合法权益。现就 2024 年度的履职情况汇报 如下： 一、独立董事基本情况 本人曾爱民，汉族，1971 年出生，中国国籍，无境外永久居留权，博士研 究生学历。浙江工商大学会计学院教授，副院长，博士生导师。曾担任浙江工商 大学财务与会计研究所所长、财务学系主任等职。同时担任浙江省国际金融学会 智库专家、浙江大学 EDP 中心、北京当代金融培训有限公司、华夏经纬财务咨询 有限公司高级讲师和咨询顾问，为中国铝业集团、中国兵器装备集团等世界 500 强企业集团提供财务和成本方面的培训与咨询服务。现任大洋生物独立董事，兼 任浙江东方科脉电子股份有限 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 248,970,295.20, representing a 27.78% increase compared to CNY 194,843,722.18 in the same period last year[5] - Net profit attributable to shareholders was CNY 29,343,179.68, up 73.44% from CNY 16,918,222.12 year-on-year[5] - Basic earnings per share rose to CNY 0.3607, reflecting a 74.08% increase from CNY 0.2072 in the same quarter last year[5] - Operating profit for the current period was $32,830,610.45, up 83.3% from $17,891,627.59 in the previous period[18] - Net profit for the current period was $29,328,948.01, representing a 73.4% increase from $16,918,222.12 in the previous period[19] - Earnings per share (EPS) for the current period was $0.3607, compared to $0.2072 in the previous period, reflecting a significant growth[19] Cash Flow - The net cash flow from operating activities surged to CNY 42,610,970.40, a remarkable increase of 24,070.81% compared to CNY 176,291.06 in the previous year[5] - Operating cash flow for the current period is ¥42,610,970.40, a significant increase from ¥176,291.06 in the previous period[20] - Total cash inflow from operating activities is ¥228,516,777.26, compared to ¥177,121,488.87 in the prior period, reflecting a growth of approximately 29%[20] - Cash outflow from operating activities is ¥185,905,806.86, slightly up from ¥176,945,197.81, resulting in a net cash flow from operating activities of ¥42,610,970.40[20] - Investment cash inflow is ¥68,539,082.22, a substantial increase from ¥692,864.50 in the previous period[20] - Net cash flow from investment activities is ¥4,468,256.98, recovering from a negative cash flow of -¥26,556,560.83 in the prior period[20] - Total cash inflow from financing activities is ¥71,940,000.00, down from ¥129,039,694.43 in the previous period[21] - Net cash flow from financing activities is -¥48,564,510.57, an improvement from -¥55,746,748.63 in the prior period[21] - The ending cash and cash equivalents balance is ¥346,190,068.30, compared to ¥299,853,950.19 at the end of the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,654,898,791.87, showing a slight increase of 0.08% from CNY 1,653,549,319.97 at the end of the previous year[5] - Total liabilities decreased to $572,339,692.51 from $600,399,526.09 in the previous period, indicating improved financial stability[17] - The total current assets amount to ¥695,529,906.75, slightly up from ¥690,549,046.95[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,959[11] - The top 10 shareholders hold a combined 29.29% of the shares, with the largest shareholder, Chen Yanggui, owning 8.86%[11] - The company has no preferred shareholders or significant changes in the top 10 shareholders due to margin trading[13] - The company is actively involved in employee stock ownership plans, with significant holdings by key individuals[12] - There are no reported changes in the status of shares due to margin trading or lending activities among the top shareholders[13] Research and Development - The company reported a significant increase in research and development expenses, which reached CNY 8,948,093.95, a 35.06% rise from CNY 6,625,360.56 in the prior year[8] - Research and development expenses rose to $8,948,093.95, up from $6,625,360.56, highlighting the company's commitment to innovation[18] Other Financial Metrics - The accounts receivable increased by 51.56% to CNY 89,047,616.80, primarily due to delayed payments from major clients[8] - The company experienced a 84.54% increase in notes payable, amounting to CNY 94,335,216.40, attributed to higher payment obligations for goods received[8] - The company recorded a significant increase in sales expenses, which amounted to CNY 2,744,277.15, a 57.79% increase compared to CNY 1,739,190.20 in the same period last year[8] - Inventory at the end of the reporting period is ¥120,182,793.46, showing a marginal increase from ¥119,784,613.63[15] - Long-term equity investments increased to ¥102,618,150.25 from ¥100,970,777.38, indicating a growth of 1.63%[15] - Unallocated profits increased to $443,098,439.64 from $413,769,491.63, showing a positive trend in retained earnings[17] Audit Status - The company has not audited the first quarter report for 2025[22]

大洋生物（003017）公告，2024年营业收入9.1亿元，同比下降1.03%。归属于上市公司股东的净利润 6374.63万元，同比增长27.48%。基本每股收益0.7822元/股，同比增长26.28%。公司拟向全体股东每10 股派发现金红利3元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥909.96 million, a decrease of 1.03% compared to ¥919.45 million in 2023[17]. - Net profit attributable to shareholders increased by 27.48% to ¥63.75 million from ¥50.01 million in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥61.17 million, reflecting a growth of 5.94% compared to ¥57.74 million in 2023[17]. - Basic earnings per share rose by 26.28% to ¥0.7822 from ¥0.6194 in the previous year[17]. - The diluted earnings per share increased by 25.44% to 0.7770 CNY compared to the previous year[18]. - Total assets reached 1,653,549,319.97 CNY, reflecting a 6.91% increase from the previous year[18]. - Net assets attributable to shareholders increased by 4.36% to 1,052,160,614.17 CNY compared to the end of the previous year[18]. - The company reported quarterly revenues of 194,843,722.18 CNY in Q1, 242,374,768.48 CNY in Q2, 234,574,946.57 CNY in Q3, and 238,162,280.89 CNY in Q4[26]. - The company reported a total non-operating income of 2,578,401.26 in 2024, a significant recovery from a loss of 7,732,649.11 in 2023, and a decrease from 25,556,828.61 in 2022[28]. - The average procurement price for potassium chloride in 2024 was 2,273.37 per ton, a 19.31% decrease from the 2023 average of 2,817.45 per ton[36]. Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 63.71% to ¥66.19 million from ¥182.42 million in 2023[17]. - Investment cash inflow dropped significantly by 83.02% to $91.15 million in 2024 from $536.81 million in 2023[68]. - Net cash flow from investment activities decreased by 215.31%, resulting in a net outflow of $167.30 million in 2024 compared to a net inflow of $145.08 million in 2023[69]. - Financing cash inflow increased by 44.92% to $752.71 million in 2024 from $519.38 million in 2023[69]. - Net cash flow from financing activities improved by 187.96%, reaching $66.56 million in 2024 compared to a net outflow of $75.68 million in 2023[69]. - Cash and cash equivalents decreased by 113.62%, resulting in a net decrease of $34.28 million in 2024 compared to an increase of $251.73 million in 2023[67]. Market Position and Product Development - The company is a major supplier of 2-chloro-6-fluoro series products in both domestic and international markets, focusing on optimizing the product structure of fluorinated chemicals[34]. - The company has maintained a strong market position in the production of light potassium carbonate, which is widely used in high-end fields such as food and pharmaceuticals[32]. - The company is actively expanding its product offerings, including special specifications for potassium carbonate and ammonium bicarbonate, to strengthen its competitive advantage[39]. - The company is focusing on expanding its potassium carbonate product line, leveraging proprietary technologies that enhance production efficiency and sustainability[109]. - The company is committed to becoming the largest global supplier of hydrochloride amprolium, currently produced by only two companies, including itself[111]. Research and Development - Research and development expenses decreased by 26.60% to ¥28,783,859.27 compared to ¥39,215,227.46 in the previous year[65]. - The number of R&D personnel decreased by 7.62% to 97 from 105 in the previous year[65]. - The company has 12 invention patents and 3 utility model patents related to hydrochloric acid ammonium propylene production technology, indicating a strong focus on innovation[39]. - The company is conducting pilot tests and trial production for several R&D projects aimed at enhancing product competitiveness and reducing production costs[62]. - The company has initiated new product development projects, including potassium carbonate and hydrochloric acid amine, to explore new profit growth points[64]. Governance and Compliance - The company has established a robust internal control system to ensure compliance with governance requirements and operational efficiency[131]. - The company actively engages with investors through various communication channels, ensuring transparency and fairness in investor relations[131]. - The board of directors operates independently and adheres to legal regulations, ensuring proper governance and decision-making processes[130]. - The supervisory board maintains compliance with laws and regulations, ensuring accurate financial reporting and protecting shareholder interests[130]. - The company has established clear management responsibilities within its finance and audit departments to enhance risk management[88]. Environmental Sustainability - The company achieved a zero discharge of wastewater in the potassium carbonate production process, showcasing its commitment to environmental sustainability[39]. - The company has invested in environmental protection facilities, continuously upgrading them to comply with national standards, which may increase operational costs in the short term[122]. - The company has implemented a wastewater treatment facility with a capacity of 1500m³/d, adhering to the GB21904-2008 standard for chemical synthesis pharmaceutical industry wastewater discharge[199]. - The company has a waste gas treatment system that meets the ultra-low emission standards set by the Zhejiang Provincial Ecological Environment Department[200]. - The company has received independent approval for the transfer of surplus raised funds to working capital without needing shareholder meeting approval[97]. Strategic Initiatives - The company plans to continue expanding its market presence and product offerings in the upcoming fiscal year[95]. - The company is exploring potential mergers and acquisitions to strengthen its market position[139]. - The company plans to enhance its user data analytics capabilities to better understand customer needs and preferences[139]. - The company is set to launch new products in the upcoming quarter, aiming to capture a larger market share[169]. - The company has allocated a budget of $500 million for research and development in new technologies for 2024[170].

浙江大洋生物科技集团股份有限公司 关于收到浙江监管局对公司股东出具警示函的公告 证券代码：003017 股票简称：大洋生物 公告编号：2025-008 浙江监管局出具的《关于对杨兴礼采取出具警示函措施的决定》。 一、警示函的主要内容 "杨兴礼： 你于 2025 年 2 月 18 日通过集中竞价交易方式增持浙江大洋生物科技集团股 份有限公司（以下简称公司）股份 800,000 股。本次权益变动后，你持有公司股份 从 3,950,000 股增加为 4,750,000 股，占公司总股本比例从 4.70%增加为 5.65%。 你在持股比例达到公司已发行股份的 5%时，未在规定期限内停止交易。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 上述行为违反了《上市公司收购管理办法》（证监会令第 166 号）第十三条 第一款规定。根据《上市公司收购管理办法》（证监会令第 166 号）第七十五条 规定，我局决定对你采取出具警示函的监督管理措施，并记入证券期货市场诚信 档案。你应认真吸取教训，加强证券法律法规学习，严格规范交易行为，杜绝此 类违规行为再次发生，并于收到本决定书之 ...

浙江大洋生物科技集团股份有限公司 简式权益变动报告书 上市公司名称：浙江大洋生物科技集团股份有限公司 股票上市地：深圳证券交易所 股票简称：大洋生物 股票代码：003017 信息披露义务人：杨兴礼 住所：甘肃省兰州市城关区 通讯地址：甘肃省兰州市城关区 权益变动性质：增持股份 签署日期：2025年02月18日 信息披露义务人声明 一、本报告书依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司收购管理办法》（以 下简称"《收购办法》"）、《公开发行证券的公司信息披露内容与格式准则第15号 ——权益变动报告书》（以下简称"《准则第15号》"）及其他相关法律、法规及 部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程或内部规则中的任何条款，或与之冲突。 三、依据《证券法》《收购办法》《准则第15号》的规定，本报告书已全面 披露信息披露义务人在大洋生物中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没有 通过任何其他方式增加或减少其在大洋生物 ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-006 浙江大洋生物科技集团股份有限公司 关于股东持有公司股份达到 5%暨权益变动的提示性公告 （二）本次权益变动的目的 本次权益变动的目的系信息披露义务人基于对公司未来发展的信心及长期投 资价值的认可。 （三）本次权益变动的情况 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次权益变动属于增持，未触及要约收购。 2、本次权益变动不会导致公司控股股东及实际控制人发生变化。 浙江大洋生物科技集团股份有限公司（以下简称"公司"）于 2025 年 2 月 19 日收到股东杨兴礼（以下称"信息披露义务人"）出具的《浙江大洋生物科 技集团股份有限公司简式权益变动报告书》及相关资料，具体情况如下： 一、本次增持情况 （一）信息披露义务人的基本情况 | 姓名 | 杨兴礼 | | --- | --- | | 性别 | 男 | | 住所 | 甘肃省兰州市城关区 | | 通讯地址 | 甘肃省兰州市城关区 | | 身份证号码 | 6501061964******** | | 是否取得其他国家或者地区 ...